



PATENT  
Customer No. 22,852  
Attorney Docket No. 06478.1478

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Bernhard NIESWANDT

Application No.: 10/051,168

Filed: January 22, 2002

For: MEDICAMENT FOR THE  
PROTECTION AGAINST  
THROMBOTIC DISEASES

)  
)  
) Group Art Unit: 1644  
)  
) Examiner: M. HADDAD  
)  
)  
)  
)  
)

Commissioner for Patents  
Washington, DC 20231

Sir:

RECEIVED  
APR 25 2003  
TECH CENTER 1600/2900  
  
RECEIVED  
APR 24 2003  
GROUP 1700

AMENDMENT

In response to the Office Action mailed October 22, 2002, the shortened statutory period for a response having been extended to April 22, 2003, by the attached Petition for Extension of Time and fee, please amend this application as follows:

IN THE SPECIFICATION:

Please amend the Specification as follows:

Page 3, amend the paragraph bridging lines 13-22 as follows:

Based on these results, it has now been found that a medicament is effective against thrombotic diseases if it comprises an active principal that induces an irreversible inactivation or degradation of a collagen receptor on thrombocytes. This active principal may be a chemical compound or a monoclonal or polyclonal antibody.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com